Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Receivables: 2014-2024

Historic Receivables for ImmunityBio (IBRX) over the last 3 years, with Dec 2024 value amounting to $2.4 million.

  • ImmunityBio's Receivables rose 587.17% to $33.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.8 million, marking a year-over-year increase of 440.72%. This contributed to the annual value of $2.4 million for FY2024, which is N/A change from last year.
  • Latest data reveals that ImmunityBio reported Receivables of $2.4 million as of FY2024, which was down 26.02% from $3.2 million recorded in FY2022.
  • In the past 5 years, ImmunityBio's Receivables registered a high of $3.2 million during FY2022, and its lowest value of $2.4 million during FY2024.
  • For the 2-year period, ImmunityBio's Receivables averaged around $2.8 million, with its median value being $2.8 million (2022).